BrC16-T

BrC16-T is a hydrophobic, brominated 16-carbon acyl-chain derivative of the microtubule-stabilizing agent paclitaxel. It was developed to facilitate the formation of "lipocores"—solid, spherical lipid-coated drug particles characterized by a high drug-to-lipid ratio (typically >90:10) and the absence of an internal aqueous volume. These lipocore particles are formed via a kinetic trapping process using PEG-conjugated lipids (such as DSPE-PEG2000). Preclinical studies in SCID mice bearing human ovarian carcinoma (OvCar3) indicate that BrC16-T lipocores are significantly less toxic than conventional paclitaxel (Taxol) after intravenous or intraperitoneal administration while maintaining potent anti-tumor activity.

Other names

2'-O-(2-bromohexadecanoyl)paclitaxelbrominated C16-paclitaxel derivative